Landmark Personalized Base Editing Therapy Cures Infant With Fatal Metabolic Disorder

In a milestone that redefines the boundaries of precision medicine, a team of scientists and clinicians has successfully cured an infant of a fatal metabolic disorder using a fully customized gene-editing therapy. The breakthrough, detailed in the New England Journal of Medicine, represents the world’s first successful application of an "N-of-1" base-editing treatment—a therapy designed from scratch for a single patient's unique genetic mutation.[1][2]

The patient, a baby boy named KJ Muldoon, was born with severe carbamoyl phosphate synthetase 1 (CPS1) deficiency. This ultra-rare metabolic disease affects roughly one in 1.3 million infants and carries a mortality rate of approximately 50 percent in early infancy. Within 48 hours of his birth, KJ exhibited severe lethargy and respiratory distress, the hallmarks of a rapidly escalating metabolic crisis.[1][5]

CPS1 deficiency fundamentally breaks the body's urea cycle. During the normal digestion of dietary protein, the body produces ammonia as a toxic byproduct. In a healthy liver, the CPS1 enzyme acts as the crucial first step in converting that toxic ammonia into harmless urea, which is then safely excreted in urine.[1][7]

Because KJ carried a specific genetic mutation known as Q335X—a single-letter typo in his DNA—his liver cells produced a truncated, non-functional version of the CPS1 enzyme. Without it, ammonia rapidly accumulated in his bloodstream, spiking to levels exceeding 1,000 micromoles per liter, far above the normal range of 9 to 33. At these concentrations, ammonia is highly toxic to the central nervous system, causing irreversible brain damage, coma, and eventually death.[2][7]

The standard of care for CPS1 deficiency is notoriously grim. Clinicians rely on extreme dietary protein restriction and heavy doses of nitrogen-scavenging medications to temporarily manage ammonia levels. The only long-term solution is a liver transplant, but infants as young and fragile as KJ are rarely viable candidates for such a massive surgical intervention. Facing a rapidly closing window, KJ’s medical team at the Children's Hospital of Philadelphia (CHOP) and Penn Medicine proposed a radical alternative: building a genetic cure from scratch.[1][6]

The researchers turned to a next-generation genetic technology known as base editing. While traditional CRISPR-Cas9 operates like molecular scissors—cutting through both strands of the DNA double helix to disable or insert genes—base editing functions more like a chemical pencil eraser. It uses a modified CRISPR protein to navigate to a precise location in the genome, where a specialized enzyme chemically converts a single DNA letter into another without breaking the DNA strand.[3][4]

This distinction is critical for safety. By avoiding double-strand breaks, base editing drastically reduces the risk of unintended genetic deletions or chaotic cellular repair processes. For KJ, the goal was to deploy an adenine base editor (ABE) to convert the faulty adenine-thymine (A-T) base pair in his CPS1 gene back into the correct guanine-cytosine (G-C) pair, thereby restoring the liver's ability to produce the full-length, functional enzyme.[3][7]

Developing a bespoke genetic medicine typically takes years, if not a decade. KJ did not have years. Leveraging the foundational research of David Liu’s lab at the Broad Institute—which originally developed the specific deaminase enzyme required for the edit—the CHOP and Penn Medicine teams mobilized an unprecedented rapid-response effort.[1][3]

Within a matter of weeks, the researchers sequenced KJ’s genome, identified the exact Q335X mutation, and began screening various base editors and guide RNAs in human cell models. Once they identified the most efficient combination, they validated the approach in mice genetically engineered to carry KJ’s specific human mutation. The results were definitive: the base editor successfully corrected the mutation and restored enzyme function.[2][4]

To translate this biological blueprint into a clinical-grade drug, the academic teams partnered with industry leaders, including Danaher Corporation and its subsidiaries Aldevron and Integrated DNA Technologies (IDT). Together, they manufactured the custom guide RNA and the mRNA encoding the base editor. The genetic payload was then encapsulated in lipid nanoparticles (LNPs)—microscopic fat bubbles similar to those used in mRNA vaccines—which naturally home in on the liver when injected into the bloodstream.[6][7]

The entire pipeline, from genetic diagnosis to a manufactured, clinical-grade drug product dubbed "k-abe," was compressed into just six months. Operating under a single-patient emergency use protocol authorized by the FDA, clinicians administered the first intravenous infusion to KJ in February 2025, when he was just over six months old.[1][6]

The biochemical response was immediate and profound. Within seven weeks of the initial treatment, KJ's blood ammonia levels plummeted. By his second dose, his median ammonia levels had stabilized at a healthy 13 micromoles per liter. The base editor had successfully rewritten the genetic code in enough of his liver cells to restore the urea cycle.[1][2]

Now, more than a year after that first historic infusion, the clinical outcomes have surpassed the team's most optimistic projections. As of late 2026, KJ is walking, talking, and thriving. He is able to tolerate significantly higher levels of dietary protein, requires less than half of his original nitrogen-scavenging medication, and successfully navigates common childhood viral infections without experiencing the dangerous ammonia spikes that previously threatened his life.[1][7]

The success of KJ’s treatment establishes a monumental proof-of-concept for the future of rare disease medicine. There are thousands of known genetic mutations that cause severe, often fatal, rare diseases. Because these conditions affect only a handful of patients globally, they are typically ignored by traditional pharmaceutical development models, which require massive patient populations to recoup the costs of decade-long clinical trials.[4][5]

By proving that a customized guide RNA can be rapidly swapped into a proven lipid nanoparticle delivery system, this case lays the groundwork for a scalable "N-of-1" therapeutic model. While the logistical and financial hurdles of manufacturing bespoke drugs for individual patients remain immense, the biological barrier has been definitively broken. For the first time in medical history, scientists have demonstrated that when faced with a fatal genetic typo, they can simply write a new ending.[2][7]